Oxidative stress and HIV infection: Target pathways for novel therapies?

Future HIV Therapy

Volumn 2, Issue 4, 2008, Pages 327-338

  Aquaro, Stefano ^a   Scopelliti, Fernanda ^b   Pollicita, Michela ^b   Perno, Carlo Federico ^b  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antioxidant; HIV; HIV associated dementia; Lymphocytes; Macrophages; Oxidative stress; ROS

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ASCORBIC ACID; BIOFLAVONOID; CURCUMIN; EPIGALLOCATECHIN GALLATE; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); MEMANTINE; PEROXYNITRITE; POLYPHENOL DERIVATIVE; PROCYANIDIN; RETINOL; SELEGILINE; SELENIUM; TANNIN; TETRAKIS (4 BENZOIC ACID)PORPHYRIN CHLORIDE MANGANESE; THIOREDOXIN REDUCTASE; TRACE ELEMENT; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG; VITAMIN; ZINC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REVIEW; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 52349117579     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.4.327     Document Type: Review

References (92)

1. Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Selnes OA, McArthur JC: Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J. Neurovirol. 6, 84-88 (2000).
2. Strawford A, Hellerstein M: The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin. Oncol. 25, 76-81 (1998).
3. Pace GW, Leaf CD: The role of oxidative stress in HIV disease. Free Radic. Biol. Med. 19, 523-528 (1995).
4. Chiueh CC, Rauhala P: The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell-to-neuron communications. Free Radic. Res. 31, 641-650 (1999).
5. Reynolds A, Laurie RC, Mosley L, Gendelman HE: Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 82, 297-325 (2007).
6. Kondala RA, Mantovani J, Herzenberg LA, Herzenberg LA: N-acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 7, 355-359 (2007).
7. Schafer FQ, Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30, 1191-1212 (2001).
8. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. Oxford University Press, NY, USA 3 (1999).
9. Anderson E, Zink W, Xiong H, Gendelman HE: HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J. Acquir. Immune Defic. Syndr. 31, S43-S54 (2002).
10. Mollace V, Nottet HS, Clayette P et al.: Oxidative stress and NeuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci. 24, 411-416 (2001).
11. Nakamura H, Masutami H, Yodoi J: Redox imbalance and its control in HIV infection. Antioxid. Redox Signal. 4, 455-464 (2001).
12. Scheel-Toellner D, Wang KQ, Craddock R et al.: Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood 104, 2557-2564 (2004).
13. Scheel-Toellner D, Wang KQ, Webb PR et al.: Early events in spontaneous neutrophil apoptosis. Biochem. Soc. Trans. 32, 461-464 (2004).
14. Lee MW, Park SC, Yang YG et al.: The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis. FEBS Lett. 512, 313-318 (2002).
15. Zhang X, Shan P, Sasidhar M et al.: Reactive oxygen species and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinese mediate hyperoxia-induced cell death in lung epithelium. Am. J. Respir. Cell Mol. Biol. 28, 305-315 (2003).
16. Salmen S, Montes H, Soyano A et al.: Mechanisms of neutrophil death in human immunodeficiency virus-infected patients: role of reactive oxygen species, caspases and map kinase pathways. Clin. Exp. Immunol. 150(3), 539-545 (2007).
17. Buhl R, Jaffe HA, Holroyd KJ et al.: System glutathione deficiency in symptom-free HIV seropositive individuals. Lancet 2, 1294-1298 (1989).
18. Choi J, Liu RK, Kundu F et al.: Molecular mechnism of decreased glutathione content in human immunodeficiency virus type 1 TAT transgenic mice. J. Biol. Chem. 275, 3693-3698 (2000).
19. Herzemberg LA, De Rosa SC, Dubs JG et al.: Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl Acad. Sci. 94, 1967-1972 (1997).
20. Cohen I, Boya P, Zhao L et al.: Anti-apoptotic activity of the glutathione peroxidase homologue encoded by HIV. Apoptasis 9(2), 181-192 (2004).
21. Richard MJ, Guirad C, Didier M, Seve M, Flores SC, Favier A: Human immunodeficiency virus type 1 TAT protein impairs selenoglutathione peroxidise exspression and activity by a mechanism independent of cellular selenium uptake: consequences on cellular resistance to UV-A radiation. Arch. Biochem. Biophys. 386, 213-220 (2001).
22. Flores SC, Marecki JC, Harper KP, Bose SK, Nelson SK, McCord JM: TAT protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in Hela cells. Proc. Natl Acad. Sci. USA 90, 7632-7636 (1993).
23. Garaci E, Palamara AT, Ciriolo MR et al.: Intracellular GSH content and HIV replication in human macrophages. J. Leukoc. Biol. 62(1), 54-59 (1997).
24. Price TO, Uras F, Banks WA, Ercal N: A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp. Neurol, 201(1), 193-202 (2006).
25. Saha RN, Pahan K: Differential regulation of Mn-superoxide dismutase in neurons and astroglia by HIV-1 gp120: implications for HIV-associated dementia. Free Radic Biol. Med. 42, 1866-1878 (2007).
26. Galicia O, Sánchez-Alavez M, Méndez Díaz M, Navarro L, Prospero-García O: HIV glycoprotein 120: possible etiological agent of AIDS-associated dementia. Rev. Invest. Clin. 54, 437-452 (2002).
27. Corasaniti MT, Strangoli MC, Piccirilli S et al.: Apoptosis Induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem. Biophys. Res. Commun. 274 (3), 664-669 (2000).
28. Zhao L, Olubajo B, Taylor EW: Functional studies of an HIV-1 encoded glutathione peroxidase. Biofactors 27(1-4), 93-107 (2006).
29. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND: Glutathione metabolism and its implications for health. J. Nutr. 134(3), 489-492 (2004).
30. Bertini R, Howard OM, Dong HF et al.: Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J. Exp. Med. 189(11), 1783-1789 (1999).
31. Lizette G, Martinez G, Gonzalez I et al.: Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol. Res. 47, 217-224 (2003).
32. Holmgren A: Thioredoxin. Annu. Rev. Biochem. 54, 237-271 (1981).
33. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J: AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl Acad Sci. USA 94 (8), 3633-3638 (1997).
34. Nakamura H, Stephen C, De Rosa J et al.: Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc. Natl Acad. Sci. USA 98, 2688-2693 (2001).
35. +, T or monocytic cell lines. J. Virol. 72, 9698-9705 (1998).
36. Kuritzkes DR: Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin. Infect. Dis. 30, 256-260 (2000).
37. Kucharzik T, Williams IR: Neutrophil migration across the intestinal epithelial barrier: summary of in vitro data and description of a new transgenic mouse model with doxycycline-inducible interleukin-8 expression in intestinal epithelial cells. Pathobiology, 70, 143-149 (2003).
38. Sulltana R, Newman S, Mohammad-Abdul H, Keller JN, Butterfield DA: Protective effect of the xanthate, D609, on Alzheimer's amyloid β-peptide-induced oxidative stress in primary neuronal cells. Free Radic. Res. 38, 449-458 (2004).
39. Zhou D, Lauderback CM, Yu T, Brown SA, Butterfield DA, Thompson JS: D609 inhibits ionizing radiation-induced oxidative damage by acting as a potent antioxidant. J Pharmacol. Exp. Ther. 298, 103-109 (2001).
40. Pocernich CB, La Fontaine M, Butterfield DA: In vivo gluthatione elevation protects against hydroxyl free radical-induced protein oxidation in mouse brain: involvement of cytokines. Virology, 205, 519-529 (1994).
41. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA: Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem. Int. 39, 141-149 (2001).
42. McArthur JC, Haughey N, Gartner S et al.: Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9(2), 206-221. (2003).
43. Aquaro S, Svicher V, Ronga L, Perno CF, Pollicita M: HIV-1-associated dementia during HAART therapy. Recent Patents CNS Drug Discov. 3(1), 23-33 (2008).
44. Aquaro S, Panti S, Caroleo MC: Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J. Leukoc. Biol. 68(3), 429-435 (2000).
45. Beckman JS: Oxidative damage and t yrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9, 836-844 (1996).
46. + T cells. AIDS 11, 1103-1110 (1997).
47. Stehbens WE: Oxidative stress, toxic hepatitis, and antioxidants with particular emphasis on zinc. Exp. Mol. Pathol. 75, 265-276 (2003).
48. Stehbens WE: Oxidative stress in viral hepatitis and AIDS. Exp. Mol. Pathol. 77(2), 121-132 (2004).
49. Webb AL, Villamor E: Update: effects of antioxidant and non-antioxidant vitamin supplementation on immune function. Nutr. Rev. 65(5), 181-217 (2007).
50. Pocernich CB, Rukshana S, Hafiz M, Nath A, Butterfield DA: HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res. 50, 14-26 (2005).
51. Harakeh S, Jariwalla RJ, Pauling L: Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc. Natl Acad. Sci. USA 87, 7245-7249 (1990).
52. Israel N, Gougerot-Pocidalo MA, Aillet F, Virelizier JL: Redox status of cells influences constitutive or induced NF-κB translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J. Immunol. 149, 3386-3393 (1992).
53. Fawzi WW, Msamanga GI, Spiegelman D: A randomized trial of multivitamin supplements and HIV disease progression and mortality. N. Engl. J. Med. 351, 23-32 (2004).
54. Hori K, Hatfield D, Maldarelli F: Selenium supplementation suppresses tumor necrosis factor-α-induced human immunodeficiency virus type 1 replication in vitro. AIDS Res. Hum. Retroviruses 13, 1325-1332 (1997).
55. Sappey C, Legrand-Poels S, Best-Belpomme M, Favier A, Rentier B, Piette J: Stimulation of gluthathione peroxidase activity decreases HIV type 1 activation after oxidative stress. AIDS Res. Hum. Retroviruses 10, 1451-1461 (1998).
56. Kupka R, Msamanga GI, Spiegelman D et al.: Selenium status is associated with accelerated HIV disease progression among HIV-1-infected pregnant women in Tanzanla. J. Nutr. 134, 2556-2560 (2004).
57. Foster HD: A role for the antioxidant defense system in preventing the transmission of HIV. Med. Hypotheses 69(6), 1277-1280 (2007).
58. Mocchegiani E, Muzzioli M: Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J. Nutr. 130, 1424S-1431S (2000).
59. Berg, K, Bolt G, Anderson H, Owen TC: Zinc potentiates the antiviral action of human IFN-α tenfold. J. Interferon Cytokine Res. 21, 471-474 (2001).
60. Prasad AS; Effects of zinc deficieney on Th1 and Th2 cytokine shifts. J. Infect. Dis. 182, S62-S68 (2000).
61. Campa A, Shor-Posner G, Lai H et al.: Zinc supplementation in zinc-deficient HIV-1 seropositive subjects. Int. Conf. AIDS 12, 1084 (1998).
62. Bjugstad KB, Flitter WD, Garland WA, Su GC, Arendesh GW: Preventive action of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 795(1-2), 349-357 (1998).
63. Butterfield D, Cestegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V: Nutritional approaches to combat oxidative stress in Alzheimer's disease. J. Nutr. Biochem. 13, 444 (2002).
64. Sakagami H, Asano K, Satoh K et al.: Anti-stress, anti-HIV and vitamin C-synergized radical scavenging activity of mulberry juice fraction. In Vivo 21 (3), 499-505 (2007).
65. Monick MM, Carter AB, Gudmundsson R, Mallampalli R, Powers LS, Hunninghake GW: Phosphatidylcoline-specific phospholipase C regulates activation of p42/44 mitogen activated protein kinases in lipopolysaccaride-stimulated human alveolar macrophages. J. Immunol. 162, 3005-3012 (1999).
66. Sauer G, Amtmann K, Melber A et al.: DNA and RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique properties. Proc. Natl Acad. Sci. USA 81, 3263-3267 (1984).
67. Amtmann E: The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp. Clin. Res. 22, 287-294 (1996).
68. Mellert W, Amtmann E, Erfle V: Inhibition of HIV-1 replication by an antiviral xanthate compound in vitro. AIDS Res. Hum. Retroviruses 4, 71-81 (1988).
69. Lauderback CM, Drake J, Zhou D et al.: Derivatives of xanthic acid are novel antioxidants: application to synaptosomes. Free Radic. Res. 37, 355-365 (2003).
70. Hayman M, Arbuthnott G, Harkiss G et al.: Neurotoxicity of peptide analogues of the transactivating protein Tat from Maedi-Visna virus and human immunodeficiency virus. Neuroscience 53, 1-6 (1993).
71. Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA: Elevation of brain glutathione by γ-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J. Neurosci. Res. 68, 776-784 (2002).
72. Drake J, Sultana R, Aksenova M, Calabrese V, Butterfield DA: Elevation of mitochondrial glutathione by γ-glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. J. Neurosci. Res. 74, 917-927 (2003).
73. Oiry J, Mialocq P, Puy P: Synthesis and biological evaluation in human monocyte-derived macrophages of N-(N-acetyl-L-cysteinyl)-S-acetylcysteamine analogues with potent antioxidant and anti-HIV activities. J. Med. Chem. 47, 1789-1795 (2004).
74. Takagi Y, Mitsui A, Nishiyama A: Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl Acad Sci. USA 96, 4131-4136 (1999).
75. Mitsui A, Hamuro J, Nakamura H et al.: Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox Signal. 4(4), 693-696 (2002).
76. Nakamura H, Masutani H, Yodoi J et al.: Redox imbalance and its control in HIV infection. Antioxid. Redox Signal. 4, 455-464 (2002).
77. Steiner JP, Galey D, Haughey NJ, Asch D, Nath A: Neuroprotective and antiretroviral effects of the immunophilin ligand GPI 1046. J. Neuroimmune Pharmacol. 2(1), 49-57 (2007).
78. Lipton SA: Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 42, 1403-1405 (1993).
79. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD: Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. 47, 186-194 (2000).
80. Toggas SM, Masliah E, Mucke L: Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. 706, 303-307 (1996).
81. Aquaro S, Muscoli C, Ranazzi A et al.: The contribution of peroxynitrite generation in HIV replication in human primary macrophages. Retrovirology 21, 4-76 (2007).
82. +: potential for HIV-1 therapy. J. Allergy Clin. Immunol. 118(6), 1369-1374 (2006).
83. Calabrese V, Scapagnini G, Colombrita C et al.: Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25, 437-444 (2003).
84. Calabrese V, Scapagnini G, Lavagna A et al.: Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech. Ageing Dev. 125, 325-335 (2004).
85. Scapagnini G, Foresti R, Calabrese V et al.: Caffeic acid phenetyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol. Pharmacol. 61, 554-561 (2002).
86. Schifitto G, Zhang J, Evans SR et al.: A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment Neurology 69(13), 1308 (2007).
87. Mollace V, Salvemini D, Riley DP et al.: The contribution of oxidative stress in apoptosis of human cultured astroglial cells induced by supernatants of HIV-1-infected macrophages J. Leukoc. Biol. 71, 65-72 (2002).
88. Salvemini, D, Wang ZQ, Stern MK, Currie MG, Misko TP: Peroxynitrite decomposition catalyst: therapeutics for peroxynitrite-mediated pathology. Proc. Natl Acad. Sci. USA 95, 2659-2663 (1998).
89. Salvemini D, Wang ZQ, Zweier JL et al.: A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 286, 304-306 (1999).
90. Aukrust P, Müller F, Svardal AM et al.: Disturbed glutathione metabolism and decreased antioxidant levels in human immonodeficiency virus-infected patients during highly active antiretroviral therapy-potential immunomodulatory effects of antioxidants. J. Infect. Dis. 188, 232-238 (2003).
91. Spada C, Treitinger A, Reis M et al.: An evaluation of antiretroviral therapy associated with α-tocopherol supplementation in HIV-infected patients. Clin. Chem. Lab. Med. 40, 456-459 (2002).
92. De Rosa SC, Zaretsky MD, Dubs JG et al.: N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Invest. 30, 915-929 (2000).